EDP-323

About Enanta Pharmaceuticals

Enanta Pharmaceuticals is a publicly traded biotech focused on creating novel oral therapeutics through innovative chemistry, with a proven track record in virology. The company's past success includes collaborating with AbbVie to discover two protease inhibitors (glecaprevir and paritaprevir) that are part of marketed HCV regimens that have cured over one million patients. Its current strategy is to replicate this success in new areas, with a clinical-stage pipeline targeting RSV and earlier-stage immunology programs for type 2 inflammatory diseases. Enanta is led by a seasoned management team and is driven by a mission to transform patient lives with curative therapies.

Therapeutic Areas

Other Respiratory Syncytial Virus (RSV) Infection Drugs